Navigation Links
Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
Date:12/5/2013

BURLINGTON, Mass., Dec. 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-small-cell lung cancer (NSCLC), biomarker testing is already widely employed in the China and South Korea markets, and is set to increase to European levels in the next two years.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

Decision Resources' new Emerging Markets Physician & Payer Forum report entitled NSCLC in China and South Korea: Physician and Payer Perspectives on Prescribing Trends, Patient Access, and Reimbursement Challenges Facing Current and Emerging Therapies finds that surveyed oncologists in China (most of whom practice in Tier 3 hospitals) estimate that one-half of their NSCLC patients are currently tested for EGFR mutations, and that by year-end 2016 almost three-quarters will be tested. ALK–translocation testing rates are currently low, at around one-fifth of patients, but will increase even more dramatically in the next three years. Pfizer's Xalkori, an oral, dual inhibitor of ALK and c-Met, was the first targeted agent to be approved for NSCLC with a companion diagnostic test. On the basis of impressive overall response data, Xalkori received regulatory approval in China in January 2013 and became available in a number of regions about six months later. Lack of reimbursement for testing and the high cost treatment are the key barriers to testing in China, but surveyed oncologists also point to lack of patient willingness to be tested.

In South
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
2. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
3. Surveyed Endocrinologists Consider Eli Lillys Dulaglutide To Have an Edge Over Competitors for the Treatment of Type 2 Diabetes Patients Who Are Inadequately Controlled On Metformin
4. Two-Thirds of Surveyed U.S. Neurologists Have Prescribed Genzymes Aubagio to Their Multiple Sclerosis Patients at One Year Post-Launch
5. Surveyed EU5 Rheumatologists Prescribe Biologics to Approximately Half of Their DMARD-Treated Psoriatic Arthritis Patients
6. Surveyed EU5 Oncologists Plan Increased Uptake of Perjeta for HER2-Positive Breast Cancer, But Expect Reimbursement Hurdles for Perjeta Plus Kadcycla
7. Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now
8. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
9. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
10. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
11. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that certain members of the executive ... Conference to be held September 8-10, 2014 in ... Chief Executive Officer and President, is scheduled to present ... at 10:55 a.m. ET on Wednesday, September 10, 2014. ...
(Date:8/27/2014)... 27, 2014 Asterias Biotherapeutics Inc. (OTCBB: ASTY) ... Administration (FDA) to initiate a Phase 1/2a clinical trial ... spinal cord injury.  The approved trial follows the successful ... product, and is designed to assess safety and activity ... cervical spinal cord injuries, the first targeted indication for ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 2Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 3Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 4Asterias Biotherapeutics Receives U.S. FDA Clearance to Initiate Phase 1/2a Clinical Trial of AST-OPC1 in Patients with Cervical Complete Spinal Cord Injury 5
(Date:8/27/2014)... August 27, 2014 Scientists at The Scripps ... a specific signaling pathway can be associated with alcohol ... a gene, called neurofibromatosis type 1 (Nf1), which TSRI ... The new research shows Nf1 regulates gamma-aminobutyric acid (GABA), ... relaxation. , "This novel and seminal study provides ...
(Date:8/27/2014)... Georgia State University’s Center for ... $600,000 grant from the Maternal and Child Health ... to support implementation of the Autism Plan for ... youth with autism spectrum disorder. , In preparing ... Advisory Council composed of key stakeholders from across ...
(Date:8/27/2014)... Foundation scientists examined the implications for cultural diversity ... rehabilitation. The article by Anthony Lequerica, PhD, and ... acquired brain injury (ABI) rehabilitation (doi:10.3233/NRE-141079) was ... and Krch are research scientists in Traumatic Brain ... for the Northern New Jersey TBI Model System. ...
(Date:8/27/2014)... significantly improve musculoskeletal and overall health, and minimize or ... of the latest research on senior athletes (ages 65 ... Journal of the American Academy of Orthopaedic Surgeons ... aging causes an inevitable deterioration of the body and ... of related injuries such as sprains, strains and fractures; ...
(Date:8/27/2014)... Will Holbrook, CP LP, has joined ... over 15 years of experience in the prosthetics field. ... with a Bachelor of Science degree with a major ... received his graduate degree in prosthetics at Northwestern University ... Will join us at Fourroux,” says Keith Watson, owner ...
Breaking Medicine News(10 mins):Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Center for Leadership in Disability Awarded $600,000 Grant to Improve Services for Georgia’s Children and Youth with Autism 2Health News:Lifetime of fitness: A fountain of youth for bone and joint health? 2
... implants created using stem cells can only be constructed ... before the almost inevitable need for total joint replacement. ... investigating the possibilities of a biologically-engineered synthetic liquid polymer ... offering a one stop, permanent solution. ...
... caregivers to hospital patients, coordinating and providing direct care and delivering ... ensure that each of its patient-care units has an adequate number ... number of hours nurses work known as the "target level" ... flow of patients and their need for care. Too many nurses ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, March ... target levels in a large hospital, more patients died, a ... an era of nursing shortages and cost-cutting, in that the ... authors of the research, appearing in the March 17 issue ...
... By Amanda Gardner HealthDay Reporter , ... the tsunami that devastated the nuclear complex in Japan ... that any radiation from the unfolding disaster across the ... say. The chances of any radioactive plume reaching ...
... Gardner HealthDay Reporter , WEDNESDAY, March 16 (HealthDay ... treatment to show a benefit for women with a rare ... even a treatment. The drug, sirolimus (Rapamycin), improved both ... lymphangioleiomyomatosis, or LAM, according to a study published online March ...
... recent study from North Carolina State University shows that while ... has grown, fund support for park operations has been significantly ... growth endangers the more than $20 billion in economic impact ... the reduction in general-fund support for operations puts stress on ...
Cached Medicine News:Health News:Liquid biomaterials take stem cell therapy to new level 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 2Health News:Risk of hospital patient mortality increases with nurse staffing shortfalls, study finds 3Health News:When Nurse Staffing Drops, Mortality Rates Rise: Study 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 2Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 3Health News:Radiation From Japan's Nuke Disaster Unlikely to Threaten U.S., Experts Say 4Health News:Transplant Drug May Fight Rare Lung Disorder 2Health News:Transplant Drug May Fight Rare Lung Disorder 3Health News:Study shows attendance at state parks grows, even as funding decreases 2
... ultra versatile model angulates for vascular ... the height of the support leg, ... post, or double tee foot. Add ... comfort and stability. A convenient bracket ...
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... OL1000 Bone Growth Stimulators are portable, battery-powered ... noninvasive treatment of an established nonunion fracture ... and flat bones. , ... of healing of 60.7% in patients with ...
... The EBI OsteoGen surgically implanted bone growth ... of nonunions when surgery is already planned or ... the OsteoGen is totally surgically implanted, patients are ... site 24 hours a day for up to ...
Medicine Products: